Last reviewed · How we verify
NCT06208579: ARAS-P
Feasibility and Effectiveness of Augmented Reality Assistance System for Pancreatic Surgery
trial in Pancreatectomy in 20 participants. Completed in 1 November 2024.
1 September 2024
Quick facts
| Lead sponsor | Klinikum Saarbrücken, Klinik für Allgemein-, Viszeral- und Thoraxchirurgie, Chirurgische Onkologie |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 20 |
| Start date | 11 September 2023 |
| Primary completion | 1 September 2024 |
| Estimated completion | 1 November 2024 |
| Sites | 1 location across Germany |
Conditions studied
- Pancreatectomy — all drugs for Pancreatectomy →
- Augmented Reality — all drugs for Augmented Reality →
Sponsor
Klinikum Saarbrücken, Klinik für Allgemein-, Viszeral- und Thoraxchirurgie, Chirurgische Onkologie
Who can join
18 and older, any sex, with Pancreatectomy or Augmented Reality. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Pancreatic cancer necessitates surgical resection for complete tumor eradication, serving as the primary curative approach. However, pancreatic surgery is still challenging due to the organ's retroperitoneal anatomy and proximity to vital vascular systems. Thus, precise preparation and dissection of peripancreatic vessels are crucial during pancreatic surgery to reduce perioperative complications and improve oncological outcomes. The integration of preoperative computed tomography-derived reconstructed images, along with augmenting the resulting 3D model during surgical procedures, holds significant potential in this context. Augmented reality-assistance systems (ARAS) have seen use in various surgical fields, including orthopedic, plastic, and neurosurgery. Nevertheless, the application of ARAS in abdominal surgery has faced challenges related to organ shifting and deformities. The retroperitoneal nature of the pancreas, characterized by minimal intraoperative organ shifts and deformations, makes pancreatic surgery a promising candidate for ARAS. Despite this, there is a limited number of studies exploring the impact of ARAS during pancreatic surgery. Notably, existing investigations have primarily utilized augmented reality technology with 2D-display-based modalities. This prospective study aims to fill this gap by examining the usability, feasibility, and effectiveness of wearable ARAS during pancreatic surgery. By leveraging advanced technology seamlessly integrated into the surgical workflow, this research seeks to provide valuable insights into the practical application of ARAS, potentially enhancing the precision and outcomes of pancreatic surgery. The preliminary findings of this study will also be submitted for publication in a peer-reviewed journal.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
Beyond the visible: preliminary evaluation of the first wearable augmented reality assistance system for pancreatic surgery.
Javaheri H, Ghamarnejad O, Bade R, Lukowicz P, et al · · 2025 · cited 9× · PMID 38849631 · DOI 10.1007/s11548-024-03131-0 -
Enhancing Perioperative Outcomes of Pancreatic Surgery with Wearable Augmented Reality Assistance System: A Matched-Pair Analysis.
Javaheri H, Ghamarnejad O, Widyaningsih R, Bade R, et al · · 2024 · cited 5× · PMID 39711676 · DOI 10.1097/as9.0000000000000516
Verify or expand the search:
- PubMed search for NCT06208579
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Pancreatectomy
Currently open trials in the same condition.
- NCT07248527 — PAN-ICIS Study: ICIS for Early Detection of Infectious Complications in Pancreatic Surgery · active not recruiting
- NCT06939023 — Laparoscopic Versus Robot-assisted Left-sided Pancreatectomy for Benign and Pre-malignant Lesions (DIPLOMA-3) · NA · recruiting
- NCT06944587 — A New Clinical Pathway for Personalized Management of Borderline Resectable and Locally Advanced Pancreatic Cancer · recruiting
- NCT07157605 — Oncological Safety of Spleen Preservation in Left Pancreatectomy for Pancreatic Ductal Adenocarcinoma (SPLENDID) · recruiting
- NCT06714604 — Standard or Prolonged Neoadjuvant Chemotherapy Before Surgery for BR/LAPC · Phase 3 · recruiting
Other Klinikum Saarbrücken, Klinik für Allgemein-, Viszeral- und Thoraxchirurgie, Chirurgische Onkologie trials
Trials by the same sponsor.
- NCT04946591 — Feasibility and Impact of ICG and 4K Overlay in Laparoscopic Hepatic Surgery on Real-time Tumor Detection · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06208579 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Klinikum Saarbrücken, Klinik für Allgemein-, Viszeral- und Thoraxchirurgie, Chirurgische Onkologie
- Last refreshed: 5 March 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06208579.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing